Gabapentin Capsule
Product Images NDC 71335-1454

This is a dosage table for gabapentin based on renal function. The table shows the total daily doses for different creatinine clearance levels. The dosage regimen varies from 300TID to 1,200TID for patients with creatinine clearance >60 mL/min, while for patients with creatinine clearance <15 mL/min, the daily dose should be reduced proportionally. Patients on hemodialysis should receive maintenance doses based on creatinine clearance estimates and a supplemental post-hemodialysis dose. The Cockcroft and Gault equation can be used to estimate creatinine clearance.*

This text provides a table (table 2) comparing the risks of antiepileptic drugs for different indications (epilepsy, psychiatric, and other) versus placebo patients. The table provides data on the number of patients with events per 1,000 patients for both placebo and drug patients, as well as the relative risk and risk difference.*

This is a report on Adverse Reactions in Pooled Placebo-Controlled Trials in Postherpetic Neuralgia. The table shows the percentage of adverse reactions experienced by patients under Gabapentin (N=336) compared to those under Placebo (N=227). The adverse reactions are categorized according to Body as a Whole, Digestive System, Metabolic and Nutritional Disorders, Nervous System, Respiratory System, and Special Senses. The adverse reactions reported include Asthenia, Infection, Accidental injury, Diarrhea, Dry mouth, Constipation, Nausea, Vomiting, Peripheral edema, Weight gain, Hyperglycemia, Dizziness, Somnolence, Ataxia, Abnormal thinking, Abnormal gait, Incoordination, Pharyngitis, Amblyopia, Conjunctivitis, Diplopia and Otitis media. There is a note on blurred vision reported in the asterisk.*

The text provides a table of adverse reactions in epilepsy patients greater than 12 years of age, detailing the percentage of patients who experienced side effects while taking Gabapentin and a placebo. The adverse reactions are listed under different body systems such as body as a whole, cardiovascular, digestive system, nervous system, respiratory system, skin and appendages, urogenital system, and special senses. Some of the adverse reactions mentioned include fatigue, increased weight, dyspepsia, somnolence, dizziness, pharyngitis, coughing, diplopia, amblyopia, and more.*

This is a table showing the adverse reactions reported in a placebo-controlled add-on trial involving pediatric epilepsy patients aged 3 to 12 years who were given Gabapentin. The table compares adverse reaction incidence for Gabapentin compared to Placebo. The most commonly reported adverse reactions during the trial were fever, somnolence, hostility, nausea and/or vomiting, along with emotional lability.*

This is a table showing the duration of two controlled PHN studies, the dosages given to patients, and the number of patients receiving gabapentin and placebo. The target dose for Study 1 was 3,600 mg/day, while for Study 2, it was 1,800 and 2,400 mg/day. The total number of patients receiving gabapentin was 336, while those receiving placebo were 227. Dosages were given in three divided doses per day (TID).*

This appears to be a packaging label for a prescription drug called "Neurontin 300mg" made by InvaGen Pharmaceuticals. It includes information such as the dosage form (capsule), quantity per package (#90), and expiration date (MM/YY). It also provides the National Drug Code (NDC) and storage instructions. The label includes a warning to keep all drugs out of reach of children.*